Chaccour Carlos, Hammann Felix, Rabinovich N Regina
ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
Malar J. 2017 Apr 24;16(1):161. doi: 10.1186/s12936-017-1801-4.
Ivermectin is an endectocide that has been used broadly in single dose community campaigns for the control of onchocerciasis and lymphatic filariasis for more than 30 years. There is now interest in the potential use of ivermectin regimens to reduce malaria transmission, envisaged as community-wide campaigns tailored to transmission patterns and as complement of the local vector control programme. The development of new ivermectin regimens or other novel endectocides will require integrated development of the drug in the context of traditional entomological tools and endpoints. This document examines the main pharmacokinetic and pharmacodynamic parameters of the medicine and their potential influence on its vector control efficacy and safety at population level. This information could be valuable for trial design and clinical development into regulatory and policy pathways.
伊维菌素是一种内吸性杀虫剂,在单剂量社区防治运动中广泛用于控制盘尾丝虫病和淋巴丝虫病已有30多年。目前人们对使用伊维菌素方案减少疟疾传播的潜在用途感兴趣,设想将其作为根据传播模式量身定制的社区范围运动,并作为当地病媒控制计划的补充。开发新的伊维菌素方案或其他新型内吸性杀虫剂将需要在传统昆虫学工具和终点的背景下对药物进行综合开发。本文档研究了该药物的主要药代动力学和药效学参数及其在人群水平上对其病媒控制效果和安全性的潜在影响。这些信息对于试验设计以及进入监管和政策途径的临床开发可能具有重要价值。